New genetic test for cancer recurrence

Researchers have discovered a new genetic test which could help predict cancer recurrence, paving the way for more precise, personalised treatments. Mitochondrial genes can be checked routinely in biopsies of patients diagnosed with various tumour types, including breast, lung, ovarian or gastric cancers. And they prove more accurate than current methods of predicting a patient’s response to treatment.

Scientists identified the new measures by looking at the expression levels of mitochondrial genes in samples from post-treatment cancer patients. “Early detection of cancer recurrence is everything; if we have information about a patient’s prognosis we can act much more effectively,” said Michael Lisanti, Professor of Translational Medicine at the University of Salford, and a co-author of the study. “You never know if cancer will return or how to prepare for that, so knowing who will and who won’t respond well to treatment offers reassurance to doctors, patients and families, and allows a degree of closer monitoring.”

Professor Lisanti who describes mitochondria as “the engine room of cancer stem cells” – the cells that cause metastasis – looked at more than 400 mitochondrial genes and found many to be more accurate in the prediction of recurrence or metastasis than standard cell proliferation markers, such as Ki67 or PCNA.

 

Other news

Upcoming Events

World Congress of the International Federation of Biomedical Laboratory Science (IFBLS)

Palazza dei Congressi of Firenze
22-26 September 2018

Infection Prevention 2018

Scottish Events Campus, Glasgow
30 September - 2 October 2018

Going Overboard with Microbiology - Women and Children First

Merseyside Maritime Museum, Albert Dock, Liverpool
19 October 2018

Lab Innovations 2018

NEC, Birmingham
31 October - 1 November 2018

Latest Issue

Pathology In Practice

Pathology In Practice

Aug 2018

Cryotomy in a Mohs service: the Welsh experience

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.